Treatment of Acute Myeloid Leukemia in the Community Setting

Author:

Al-Juhaishi Taha1ORCID,Dela Cruz Servillano2,Gupta Rohan3,Keiffer Gina4,Morrison Vicki A5,Shapira Iuliana6,Woods Ashley7,Norsworthy Kelly7,de Claro Romeo Angelo7,Theoret Marc R8,Garg Ravin9,Pulte Elizabeth Dianne7

Affiliation:

1. Oklahoma Health Sciences Center, University of Oklahoma , Oklahoma City, OK , USA

2. Florida Cancer Specialists & Research Institute , Inverness, FL , USA

3. The Center for Cancer and Blood Disorders , Fort Worth, TX , USA

4. Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia, PA , USA

5. Hennepin County Medical Center, University of Minnesota , Minneapolis, MN , USA

6. Regional Cancer Care Associates , Teaneck, NJ , USA

7. Center for Drug Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA

8. Oncology Center of Excellence, U.S. Food and Drug Administration , Silver Spring, MD , USA

9. Maryland Oncology and Hematology , Annapolis, MD , USA

Abstract

Abstract The treatment landscape for acute myeloid leukemia (AML) is rapidly changing. Many new agents and lower-intensity regimens have been approved and can be safely used by hematologists and oncologists in both academic and community settings. The US Food and Drug Administration (FDA) held a virtual symposium on AML treatment in the community in November 2022. Several members of the FDA, along with practicing hematologists and oncologists in both academic and community settings, participated in the symposium. The goal of the symposium was to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.

Publisher

Oxford University Press (OUP)

Reference25 articles.

1. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia;Röllig,2020

2. Acute myeloid leukemia: 2019 update on risk-stratification and management;Estey,2018

3. Acute myeloid leukemia: current progress and future directions;Kantarjian,2021

4. Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how;Loke,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3